Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid

Abstract

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(E)-octadec-9-enoic acid to treat such diseases.

1 . A method of treating pulmonary arterial hypertension (PAH), comprising:
 administering to a human patient with PAH an oral daily dose of 10-nitro-9(E)-octadec-9-enoic acid in an amount greater than 25 milligrams and less than 450 milligrams per day.   
     
     
         2 . The method of  claim 1 , wherein the oral daily dose is 75-300 milligrams. 
     
     
         3 . The method of  claim 2 , wherein the oral daily dose is 150 milligrams. 
     
     
         4 . The method of  claim 1 , wherein the oral daily dose is a single undivided dose.